Q2 EPS Forecast for Thermo Fisher Scientific Cut by Analyst

Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) - Investment analysts at Leerink Partnrs cut their Q2 2025 EPS estimates for Thermo Fisher Scientific in a report issued on Wednesday, April 23rd. Leerink Partnrs analyst P. Souda now anticipates that the medical research company will earn $5.23 per share for the quarter, down from their previous estimate of $5.41. The consensus estimate for Thermo Fisher Scientific's current full-year earnings is $23.28 per share. Leerink Partnrs also issued estimates for Thermo Fisher Scientific's Q3 2025 earnings at $5.41 EPS, Q4 2025 earnings at $6.60 EPS and FY2025 earnings at $22.39 EPS.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share for the quarter, topping the consensus estimate of $5.10 by $0.05. The firm had revenue of $10.36 billion for the quarter, compared to analysts' expectations of $10.23 billion. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. The business's quarterly revenue was up .2% on a year-over-year basis. During the same quarter in the prior year, the firm posted $5.11 earnings per share.

TMO has been the topic of a number of other research reports. Stifel Nicolaus reduced their target price on Thermo Fisher Scientific from $665.00 to $620.00 and set a "buy" rating on the stock in a research note on Thursday, April 24th. Evercore ISI cut their price target on shares of Thermo Fisher Scientific from $585.00 to $500.00 and set an "outperform" rating for the company in a research report on Thursday, April 24th. Raymond James restated an "outperform" rating and set a $667.00 price target (up from $650.00) on shares of Thermo Fisher Scientific in a research report on Monday, February 3rd. Sanford C. Bernstein upgraded shares of Thermo Fisher Scientific from a "market perform" rating to an "outperform" rating and set a $630.00 price target for the company in a research report on Friday, January 10th. Finally, Barclays cut their price target on shares of Thermo Fisher Scientific from $620.00 to $475.00 and set an "equal weight" rating for the company in a research report on Thursday, April 10th. Five analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company's stock. According to MarketBeat, Thermo Fisher Scientific currently has an average rating of "Moderate Buy" and a consensus target price of $610.27.

Thermo Fisher Scientific Price Performance

TMO traded down $0.64 during trading on Friday, reaching $426.89. The stock had a trading volume of 863,952 shares, compared to its average volume of 2,189,708. The stock has a market cap of $161.15 billion, a PE ratio of 25.83, a PEG ratio of 2.99 and a beta of 0.86. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.29 and a current ratio of 1.66. Thermo Fisher Scientific has a one year low of $409.85 and a one year high of $627.88. The business has a 50-day moving average of $482.87 and a 200-day moving average of $524.80.

Institutional Investors Weigh In On Thermo Fisher Scientific

Institutional investors have recently modified their holdings of the stock. Topsail Wealth Management LLC lifted its holdings in shares of Thermo Fisher Scientific by 96.3% during the first quarter. Topsail Wealth Management LLC now owns 852 shares of the medical research company's stock valued at $424,000 after purchasing an additional 418 shares in the last quarter. Moloney Securities Asset Management LLC lifted its holdings in shares of Thermo Fisher Scientific by 40.8% during the first quarter. Moloney Securities Asset Management LLC now owns 3,547 shares of the medical research company's stock valued at $1,765,000 after purchasing an additional 1,028 shares in the last quarter. LBP AM SA lifted its holdings in shares of Thermo Fisher Scientific by 43.3% during the first quarter. LBP AM SA now owns 230,201 shares of the medical research company's stock valued at $114,548,000 after purchasing an additional 69,507 shares in the last quarter. Axxcess Wealth Management LLC lifted its holdings in shares of Thermo Fisher Scientific by 8.3% during the first quarter. Axxcess Wealth Management LLC now owns 23,748 shares of the medical research company's stock valued at $11,817,000 after purchasing an additional 1,823 shares in the last quarter. Finally, Rehmann Capital Advisory Group lifted its holdings in Thermo Fisher Scientific by 1.7% in the first quarter. Rehmann Capital Advisory Group now owns 2,447 shares of the medical research company's stock valued at $1,218,000 after acquiring an additional 42 shares during the period. 89.23% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $516.67, for a total value of $5,166,700.00. Following the sale, the chief executive officer now directly owns 115,174 shares of the company's stock, valued at approximately $59,506,950.58. This represents a 7.99 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Michael A. Boxer sold 3,775 shares of the stock in a transaction on Monday, March 10th. The stock was sold at an average price of $532.52, for a total value of $2,010,263.00. Following the completion of the sale, the senior vice president now directly owns 10,816 shares in the company, valued at approximately $5,759,736.32. This represents a 25.87 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 23,900 shares of company stock worth $13,106,062. 0.33% of the stock is owned by insiders.

Thermo Fisher Scientific Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, April 15th. Investors of record on Friday, March 14th were paid a $0.43 dividend. The ex-dividend date of this dividend was Friday, March 14th. This represents a $1.72 annualized dividend and a dividend yield of 0.40%. This is an increase from Thermo Fisher Scientific's previous quarterly dividend of $0.39. Thermo Fisher Scientific's dividend payout ratio is presently 10.09%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.